|
KMID : 0370220140580040255
|
|
Yakhak Hoeji
2014 Volume.58 No. 4 p.255 ~ p.261
|
|
|
Measurement of CYP450 Enzymes Activity of Bosentan in HepaRG Cell
|
|
Han Kyoung-Moon
Jung Jung-A
Sin Ji-Soon
Cha Hye-Jin
Bae Young-Ji
Kim Hyun-Uk
Seong Won-Keun
Kang Ho-Il
|
|
|
Abstract
|
|
|
|
Poly-pharmacy has been on the rise because of aging of population and chronic disease. Most of drug metabolism happens in the liver by CYP isozymes and the metabolism by CYP450 enzymes. The Cytochrome P450 (CYP) is a superfamily of enzymes that catalyzes the oxidations of many endogenous and exogenous compounds. Primary human Hepatocytes (HH) are considered as the gold standard model for In vitro drug interaction studies. However, there are several limitations (cost, limited life span) for using HH cells. HepaRG cells are being used as a possible alternative. HepaRG cells were cultured in William E medium containing the positive control inducers (1A2: 10, 25, 50 μM omeprazole, 2C9 and 2C19: 10 μM rifampin, 3A4: 10, 25, 50 μM rifampin) at 37oC, 5 % CO2 in a humidified atmosphere. This study was to evaluate the induction of CYP isozymes (1A2, 2C9, 2C19 and 3A4) using LC-MS/MS. We evaluated the potential induction ability of Bosentan, as a drug of pulmonary artery hypertension, in HepaRG cells. For reference, dose of the Bosentan is determined to the basis of the Cmax (835 mg/ml) value. The enzyme activity demonstrated that CYP2C9 and 3A4 were induced up to 20 times by Bosentan. Like as In vivo, the enzyme activity of CYP2C9 and CYP3A4 is significantly induced in a dose-dependent by Bosentan.
|
|
|
KEYWORD
|
|
|
CYP450, HepaRG, LC-MS/MS, Bosentan
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|